684 views
/Unsplash

Ascendas REIT, Ascott Residence Trust, Ascendas India revise names 

The names of their managers were also changed.
 
The names of property firms, Ascendas Real Estate Investment Trust (Reit), Ascott Residence Trust (ART), and Ascendas India Trust, were modified as well as their managers. 

According to a company announcement, Ascendas REIT was changed to CapitaLand Ascendas REIT (CLAR), ART was renamed to CapitaLand Ascott Trust (CLAS), and Ascendas India Trust’s name was revised to CapitaLand India Trust (CLINT).

READ: Ascendas REIT to acquire Philips APAC Centre for $104.8m

In addition to this, CLAR’s manager is CapitaLand Ascendas REIT Management Limited, CLAR’s Reit manager is CapitaLand Ascott Trust Management Limited whilst its business trust trustee-manager is CapitaLand Ascott Business Trust Management Pte. Ltd., and CLINT’s manager is CapitaLand India Trust Management Pte. Ltd.

The revisions took effect on 27 September 2022.

Follow the links for more news on

Join Singapore Business Review community
Since you're here...

...there are many ways you can work with us to advertise your company and connect to your customers. Our team can help you dight and create an advertising campaign, in print and digital, on this website and in print magazine.

We can also organize a real life or digital event for you and find thought leader speakers as well as industry leaders, who could be your potential partners, to join the event. We also run some awards programmes which give you an opportunity to be recognized for your achievements during the year and you can join this as a participant or a sponsor.

Let us help you drive your business forward with a good partnership!

Top News

DBS and OCBC expected to deliver steady Q1 net profits
Their net interest margins will ease as a result of their Hong Kong loans.
Singapore's maritime cluster navigates towards digital, green future
Adapting to emerging challenges, such as the adoption of alternative fuels, is deemed crucial for the country's maritime sector.
SCG and A*STAR unveil joint labs for cellular immunotherapy enhancement
The partnership has a funding of nearly $30m supported under Singapore's Research, Innovation and Enterprise 2025 plan.
Healthcare